- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Atrium Therapeutics arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates | ||
| Fr | Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs | ||
| Fr | Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing | ||
| Do | 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process | ||
| Do | Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial | ||
| Do | Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial | ||
| Do | Accent halts solid tumor trial over adverse events, pivots to other lead cancer program | ||
| Mi | ARPA-H designates up to $144M for anti-aging medical research | ||
| Mi | After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate | ||
| Mi | GSK pays $950M in cash for Canadian biotech and its Winrevair-like blood pressure drug | ||
| Di | Werewolf Therapeutics weighs sale or merger as cash reserves whimper | ||
| Di | Harbour ships CTLA-4 asset to form new biotech in $1.1B biobucks deal | ||
| Di | FDA freezes enrollment in MacroGenics cancer trial after patient death | ||
| Di | Abcuro's KLRG1 antibody flunks phase 2/3 muscle disease study | ||
| Di | GSK explores frontiers of siRNA with $1B deal for 2 drugs from Chinese biotech | ||
| Di | Novo Nordisk's triple G candidate drives 20% weight loss in phase 2 trial in China | ||
| Di | Protara sees 66% 6-month bladder cancer response rate, but drops to 33% at 12 months | ||
| Di | Galapagos takes €228M hit from cell therapy wind-down but still has cash for dealmaking | ||
| Mo | 'The perfect partner': Astellas, Vir engage in $1.7B deal for masked prostate cancer bispecific | ||
| Mo | FDA illuminates new approval pathway for bespoke gene editing therapies | ||
| Mo | Angelini nocks an AI arrow with $120M Quiver Bioscience deal | ||
| Mo | Gossamer's stock sinks after phase 3 pulmonary arterial hypertension fail | ||
| Mo | Generate plans $425M IPO to bankroll antibody's phase 3 asthma trials | ||
| Mo | Gilead inks $7.8B Arcellx buyout to steer CAR-T into J&J showdown | ||
| Mo | Novo's CagriSema loses phase 3 battle with Lilly's Zepbound, knocking 15% off share price |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.